20 articles
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
Spatial-EV-seq charts where cancer-shielding vesicles cluster in tissue, exposing why immunotherapy fails in some tumor zones.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
Scientists identify a mitochondria-proteasome-haem pathway that silences immune cells — and show bortezomib can fix it in CAR-T therapy.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
Japanese trial shows dual HER2 blockade with pertuzumab plus trastuzumab improves overall survival even after prior pertuzumab treatment.
The COMPETE trial shows radioligand therapy extends progression-free survival by nearly 10 months vs. standard targeted therapy in GEP NETs.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
Scientists develop innovative immunotherapy that reprograms multiple immune cell types to attack cancer while reducing side effects.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Engineered immune cells target harmful macrophages in tumors, transforming the cancer environment to boost natural anti-tumor immunity.
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
Activated T cells release vesicles carrying genomic DNA that reprogram recipient cells to display tumor antigens more effectively.
Combining CSF1R inhibitor with chemotherapy enhanced immune response and improved outcomes in triple-negative breast cancer patients.
A new CAR T cell product called GCAR1 shows early clinical promise against rare, treatment-resistant solid tumors driven by gene fusions.
New research reveals how tiny cellular packages from aging cells might be engineered to deliver targeted cancer treatments.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
